Literature DB >> 35133000

Depleting hsa_circ_0000567 suppresses acquired gefitinib resistance and proliferation of lung adenocarcinoma cells through regulating the miR-377-3p / ZFX axis: an in vitro and in vivo study.

Lanjun Wang1, Mengqi Li2, Rong Lian3.   

Abstract

BACKGROUND: Circular RNAs (circRNAs) expression profile has been reported in lung adenocarcinoma (LUAD) cells resistant to gefitinib, and hsa_circ_0000567 was abnormally upregulated. However, its precise role in gefitinib resistance remains unclarified.
METHODS: Levels of hsa_circ_0000567, microRNA (miR)-377-3p and zinc finger protein X-linked (ZFX) were detected by real-time quantitative PCR. Direct attachment was confirmed by dual-luciferase reporter assay and RNA immunoprecipitation assay. Gefitinib resistance was measured by MTT assay, colony formation assay, flow cytometry, western blotting, and xenograft in mice.
RESULTS: Expression of hsa_circ_0000567 was upreguated in human gefitinib-resistant human LUAD tissues and cells (HCC827/GR and PC9/GR). Clinically, higher hsa_circ_0000567 correlated with advanced tumor burden. Blockage of hsa_circ_0000567 suppressed cell viability, half maximal inhibitory concentration (IC₅₀) value, colony formation ability, and expression of Bcl-2 and proliferating cell nuclear antigen (PCNA) in HCC827/GR and PC9/GR cells under gefitinib treatment or not, accompanied with enhanced apoptosis rate and Bax expression. In vivo, tumor growth of PC9/GR cells untreated and treated with gefitinib was restrained by silencing hsa_circ_0000567. miR-377-3p was directly regulated by hsa_circ_0000567, and then targeted ZFX. Similar to hsa_circ_0000567 knockdown, overexpressing miR-377-3p inhibited chemoresistance in genitinib-resistant LUAD cells in vitro, whereas, depleting miR-377-3p was able to promote gefitinib resistance in spite of hsa_circ_0000567 knockdown. Moreover, restoring ZFX abrogated miR-377-3p-mediated chemosensitivity in genitinib-resistant LUAD cells in vitro.
CONCLUSION: The hsa_circ_0000567/miR-377-3p/ZFX axis might contribute to acquired gefitinib resistance in LUAD cells both in vitro and in vivo, suggesting hsa_circ_0000567 as a novel therapeutic target in treatment of gefitinib-resistant LUAD.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35133000     DOI: 10.14670/HH-18-431

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.130


  40 in total

1.  Clinical predictors of response to EGFR-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: A real-world multicentric cohort analysis from India.

Authors:  Avneet Garg; Ullas Batra; Priyanshu Choudhary; Deepali Jain; Sachin Khurana; Prabhat S Malik; Valliappan Muthu; K T Prasad; Navneet Singh; Tejas Suri; Anant Mohan
Journal:  Curr Probl Cancer       Date:  2020-03-20       Impact factor: 3.187

Review 2.  Prognostic value of Zinc-finger protein X-linked in patients with solid tumors.

Authors:  Chao Dai; Qing Dong; Qi Lu; Fang T Liu; Zheng M Zhu
Journal:  Minerva Chir       Date:  2016-10-12       Impact factor: 1.000

Review 3.  CircRNAs and lung cancer: Biomarkers and master regulators.

Authors:  Xin Di; Xin Jin; Ranwei Li; Min Zhao; Ke Wang
Journal:  Life Sci       Date:  2019-01-31       Impact factor: 5.037

Review 4.  The biology and management of non-small cell lung cancer.

Authors:  Roy S Herbst; Daniel Morgensztern; Chris Boshoff
Journal:  Nature       Date:  2018-01-24       Impact factor: 49.962

5.  ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer.

Authors:  Ling Cai; Yi-Hsuan Tsai; Ping Wang; Jun Wang; Dongxu Li; Huitao Fan; Yilin Zhao; Rohan Bareja; Rui Lu; Elizabeth M Wilson; Andrea Sboner; Young E Whang; Deyou Zheng; Joel S Parker; H Shelton Earp; Gang Greg Wang
Journal:  Mol Cell       Date:  2018-09-27       Impact factor: 17.970

Review 6.  Critical function of circular RNAs in lung cancer.

Authors:  Rares Drula; Cornelia Braicu; Antonia Harangus; Seyed M Nabavi; Monica Trif; Ondrej Slaby; Calin Ionescu; Alexandru Irimie; Ioana Berindan-Neagoe
Journal:  Wiley Interdiscip Rev RNA       Date:  2020-03-16       Impact factor: 9.957

7.  MiR-377-3p suppresses colorectal cancer through negative regulation on Wnt/β-catenin signaling by targeting XIAP and ZEB2.

Authors:  Lifeng Huang; Zhibo Liu; Jia Hu; Zhen Luo; Cheng Zhang; Lin Wang; Zheng Wang
Journal:  Pharmacol Res       Date:  2020-03-24       Impact factor: 7.658

8.  Comprehensive analysis of circular RNA profiling in AZD9291-resistant non-small cell lung cancer cell lines.

Authors:  Tianxiang Chen; Jizhuang Luo; Yu Gu; Jia Huang; Qingquan Luo; Yunhai Yang
Journal:  Thorac Cancer       Date:  2019-03-18       Impact factor: 3.500

9.  Integrative data modeling from lung and lymphatic cancer predicts functional roles for miR-34a and miR-16 in cell fate regulation.

Authors:  Shantanu Gupta; Daner A Silveira; Florencia M Barbé-Tuana; José Carlos M Mombach
Journal:  Sci Rep       Date:  2020-02-13       Impact factor: 4.379

10.  MicroRNA-449a delays lung cancer development through inhibiting KDM3A/HIF-1α axis.

Authors:  Shan Hu; Peng Cao; Kangle Kong; Peng Han; Yu Deng; Fan Li; Bo Zhao
Journal:  J Transl Med       Date:  2021-05-27       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.